{
    "Case ID": "043813",
    "Crime_Name": [
        "Patent Infringement Dispute"
    ],
    "Crime_Type": [
        "Property Crimes"
    ],
    "Dispute_Type": [
        "Patent Infringement Dispute"
    ],
    "Legal_Issue": [
        "Whether intermediates used in the synthesis of Cefaclor are considered 'medicines' under the Regulations"
    ],
    "Governing_Law": [
        "Regulations defining 'medicine' as substances intended or capable of being used for diagnosis, treatment, mitigation, or prevention of a disease"
    ],
    "Procedural_Stage": [
        "Federal Court application"
    ],
    "Evidence_Assessment": [
        "Intermediates have no therapeutic properties and cannot be used for diagnosis, treatment, etc."
    ],
    "Decision_Outcome": [
        "Application dismissed"
    ],
    "Burden_of_Proof": [],
    "Credibility_Factor": [],
    "Legal_Rule": [
        "Substances must be intended or capable of being used for diagnosis, treatment, mitigation, or prevention of a disease to be considered 'medicines'"
    ],
    "Standard_of_Review": [
        "Statutory interpretation principles"
    ],
    "Procedural_Issue": [],
    "Grounds_for_Claim": [
        "Lilly sought to prohibit Apotex from obtaining Notices of Compliance based on patents for intermediates"
    ],
    "Outcome_on_Merits": [
        "Intermediates are not medicines; patents improperly listed"
    ],
    "Decision_Maker": [
        "Federal Court"
    ],
    "Judicial_Review_Outcome": [
        "Dismissed"
    ],
    "Review_Standard": [
        "Statutory interpretation"
    ],
    "Procedural_Fairness_Assessment": [],
    "Key_Evidence_Considered": [
        "Therapeutic properties (or lack thereof) of intermediates"
    ],
    "Legal_Framework": [
        "Regulations on definition of 'medicine'"
    ],
    "Applicant_Challenge": [
        "Lilly's attempt to block Apotex's Notices of Compliance"
    ],
    "Court_Result": [
        "Apotex can proceed with Notices of Compliance without infringing improperly listed patents"
    ],
    "Legal_Rule_Source": [
        "Regulations"
    ],
    "Standard_of_Proof": [],
    "Defendant_Response": [
        "Intermediates are not medicines and thus patent listing is improper"
    ],
    "Evidence_Type": [
        "Scientific/technical evidence on therapeutic capability"
    ],
    "Remedy_Requested": [
        "Prevention of Apotex obtaining Notices of Compliance"
    ],
    "Outcome": [
        "Dismissal of Lilly's application"
    ],
    "Decision_Authority": [
        "Federal Court"
    ],
    "Remedy_Sought": [
        "Injunction against Apotex's regulatory approval"
    ],
    "Resolution_Mechanism": [
        "Judicial determination via statutory interpretation"
    ],
    "Legal_Provision": [
        "Definition of 'medicine' in the Regulations"
    ],
    "Authority": [
        "Federal Court"
    ],
    "Claimant_Status": [
        "Lilly as patent holder"
    ],
    "Legal_Provision_Cited": [
        "Regulations defining 'medicine'"
    ],
    "Grounds_for_Inadmissibility_or_Allegation": [
        "Patents for non-medicinal intermediates improperly listed"
    ],
    "Applicable_Process": [
        "Notice of Compliance proceedings under patent linkage regulations"
    ],
    "Outcome_of_Review": [
        "Application dismissed"
    ],
    "Pending_Relief_or_Application": [],
    "Jurisdiction": [
        "Federal"
    ],
    "Governing_Rule": [
        "Statutory definition of 'medicine'"
    ]
}